Hélène M.
- Country
- France
- Department
- Service de neuropsychologie
Research Overview
- Oral semaglutide versus placebo in early Alzheimer’s disease: a randomized double-blind trial in patients with mild cognitive impairment or mild dementia
- Efficacy of Pegipanermin (XPro1595) in Early Alzheimer's Disease with Inflammatory Biomarkers: A Randomized, Double-Blind, Placebo-Controlled Trial
- Efficacy and Safety Evaluation of Lecanemab in Early Alzheimer's Disease: A Placebo-Controlled, Double-Blind, Parallel-Group Study with Open-Label Extension
Data & Insights
Has run more than one trial at 196 of 268 partner sites.
Specializations
Early Alzheimer's Disease Research
The investigator specializes in studying early-stage Alzheimer's disease and its therapeutic interventions, with particular focus on cognitive decline prevention and disease modification approaches.
- Prodromal Alzheimer's Disease
- Mild Cognitive Impairment (MCI)
- Early-stage Disease Modification
Clinical research encompasses cognitive function assessment using specialized rating scales and biomarker evaluation.
Alzheimer's Disease Psychosis
Dedicated to advancing treatment options for Alzheimer's disease with psychotic symptoms, focusing on novel therapeutic approaches for managing behavioral manifestations.
- Psychosis Management
- Long-term Safety Assessment
- Behavioral Symptom Control
Expertise includes evaluation of therapeutic interventions for complex neuropsychiatric manifestations.
Specialized Therapeutic Approaches
Investigates diverse therapeutic modalities including inflammatory biomarkers and novel pharmaceutical compounds for mild to moderate Alzheimer's disease.
- Inflammatory Pathway Research
- Cognitive Function Assessment
- Disease Progression Monitoring
Research encompasses both traditional and innovative treatment approaches in neurodegenerative conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.